why is international health insurance an important weapon in the fight against breast cancer
Facing a cancer diagnosis is one of the most challenging situations a family can experience. Early detection, accurate diagnosis and timely treatment are crucial to recovery. An international health insurance plan can be an essential element in a patient’s road to wellness. Here’s why:
International health insurance allows patients to receive treatment in top medical centers in their country and worldwide. Additionally, insureds can receive a second medical opinion to ensure their recommended treatment path is the best course to follow.
According to VUMI ® data, in 86% of cases submitted for a second medical opinion, a significant treatment change was recommended to the plan that had been suggested by the first doctor. 35% of patients who received a second medical opinion – for any illness – avoided surgery.
Waiting time and access to public healthcare services often pose serious roadblocks for patients. Opting for private services may seem the best option; however, medical check-ups and treatments can destroy a family’s finances if paid for out-of-pocket.
According to the consulting firm Willis Towers Watson, cancer is one of the most expensive diseases to treat. Estimates from the AARP (American Association of Retired Persons) show that breast cancer treatment with chemotherapy in the U.S. can cost between US$10,000 and US$100,000.
In addition, a 2022 survey by the American Cancer Society Cancer Action Network (ACS CAN) of people diagnosed with various types of cancer found the following:
- 51% of cancer patients and survivors have debt related to their cancer treatment
- 45% of these individuals delayed or avoided medical care for severe problems due to high costs
With insurance like VUMI’s, depending on the plan and options you choose, you’ll have the peace of mind of having 100% coverage for medical services such as:
- Intensive care unit
- Prescribed medications
- Specialist consultations
- Oncology exams and treatments
Global Medical Trends Survey report” – Willis Towers Watson